Abstract

Objective To investigate the expression and significance of Matriptase and HAI-1 protein in prostate cancer (CaP). Methods Specimens of 46 prostate cancers,20 benign prostate hyperplasias (BPH),10 high-grade intraepithelial neoplasias (PIN),and 10 normal prostates (NP) were used. Expressions of Matriptase and HAI-1 proteins in specimens were detected by SP of immunohistochemistry. The results were analyzed in relation to the clinicopathological data. Results The protein levels of Matriptase in CaP tissues were significantly higher than PIN tissues(Z=-2.150,P=0.032),and the expression of matriptase in CaP and PIN was higher than that in BPH and NP (Z=-3.270,P=0.001;Z=-2.817,P=0.005). No statistically significant difference was observed between BPH and NP group (Z=-0.895,P=0.325). A progressive increase in the protein levels of Matriptase was observed with increasing tumor grade (rs=0.583,P<0.01) and clinical stages(rs=0.611,P<0.01)in CaP specimens. The protein levels of HAI-1 in BPH and NP tissues were significantly higher than CaP and PIN tissues(Z=-3.277,-3.315,P<0.01),the levels of HAI-1 in PIN were higher than CaP (Z=-2.310,P=0.020). No statistically significant difference was found between BPH and NP (Z=-0.872,P=0.330). A progressive decrease in the protein levels of HAI-1 was observed with increasing tumor grades(rs=-0.634,P<0.01) and clinical stages(rs=-0.521,P<0.01). The expressions of Matriptase and HAI-1 in CaP tissues showed negative correlations(rs=-0.712,-0.560,-0.465,respectively,P<0.01). Conclusions The abnormal expressions of Matriptase and HAI-1 proteins may be important events during the progression of CaP in humans. Matriptase and HAI-1 Protein may be used as parameters for assessing the malignancy and prognosis of CaP. Key words: Serine endopeptidases/ME; Serine proteinase inhibitors/ME; Prostatic neoplasms/ME

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.